搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Proteus mirabilis Probable tRNA threonylcarbamoyladenosine biosynthesis protein Gcp (gcp) CSB-YP461498EYZ
CSB-EP461498EYZ
CSB-BP461498EYZ
CSB-MP461498EYZ
CSB-EP461498EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 3-octaprenyl-4-hydroxybenzoate carboxy-lyase (ubiD) CSB-YP461499EYZ
CSB-EP461499EYZ
CSB-BP461499EYZ
CSB-MP461499EYZ
CSB-EP461499EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Multidrug resistance protein MdtK (mdtK), partial CSB-YP461500EYZ
CSB-EP461500EYZ
CSB-BP461500EYZ
CSB-MP461500EYZ
CSB-EP461500EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis UPF0307 protein PMI3641 (PMI3641) CSB-YP461501EYZ
CSB-EP461501EYZ
CSB-BP461501EYZ
CSB-MP461501EYZ
CSB-EP461501EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA) CSB-YP461502EYZ
CSB-EP461502EYZ
CSB-BP461502EYZ
CSB-MP461502EYZ
CSB-EP461502EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis UvrABC system protein C (uvrC), partial CSB-YP461503EYZ
CSB-EP461503EYZ
CSB-BP461503EYZ
CSB-MP461503EYZ
CSB-EP461503EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Succinyl-diaminopimelate desuccinylase (dapE) CSB-YP461504EYZ
CSB-EP461504EYZ
CSB-BP461504EYZ
CSB-MP461504EYZ
CSB-EP461504EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Multidrug resistance protein MdtC (mdtC), partial CSB-YP461505EYZ
CSB-EP461505EYZ
CSB-BP461505EYZ
CSB-MP461505EYZ
CSB-EP461505EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Bifunctional purine biosynthesis protein PurH (purH), partial CSB-YP461506EYZ
CSB-EP461506EYZ
CSB-BP461506EYZ
CSB-MP461506EYZ
CSB-EP461506EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 50S ribosomal protein L7/L12 (rplL) CSB-YP461507EYZ
CSB-EP461507EYZ
CSB-BP461507EYZ
CSB-MP461507EYZ
CSB-EP461507EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Multidrug resistance protein MdtG (mdtG), partial CSB-YP461508EYZ
CSB-EP461508EYZ
CSB-BP461508EYZ
CSB-MP461508EYZ
CSB-EP461508EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis NADH-quinone oxidoreductase subunit K (nuoK), partial CSB-YP461509EYZ1
CSB-EP461509EYZ1
CSB-BP461509EYZ1
CSB-MP461509EYZ1
CSB-EP461509EYZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis UPF0208 membrane protein PMI1770 (PMI1770), partial CSB-YP461510EYZ1
CSB-EP461510EYZ1
CSB-BP461510EYZ1
CSB-MP461510EYZ1
CSB-EP461510EYZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Chorismate synthase (aroC) CSB-YP461511EYZ
CSB-EP461511EYZ
CSB-BP461511EYZ
CSB-MP461511EYZ
CSB-EP461511EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (ispG) CSB-YP461512EYZ
CSB-EP461512EYZ
CSB-BP461512EYZ
CSB-MP461512EYZ
CSB-EP461512EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis tRNA1 (Val) (adenine (37)-N6)-methyltransferase CSB-YP461513EYZ
CSB-EP461513EYZ
CSB-BP461513EYZ
CSB-MP461513EYZ
CSB-EP461513EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Aspartate--ammonia ligase (asnA) CSB-YP461514EYZ
CSB-EP461514EYZ
CSB-BP461514EYZ
CSB-MP461514EYZ
CSB-EP461514EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis ATP synthase subunit c (atpE), partial CSB-YP461515EYZ1
CSB-EP461515EYZ1
CSB-BP461515EYZ1
CSB-MP461515EYZ1
CSB-EP461515EYZ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Peptide chain release factor 2 (prfB) CSB-YP461516EYZ
CSB-EP461516EYZ
CSB-BP461516EYZ
CSB-MP461516EYZ
CSB-EP461516EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis tRNA modification GTPase MnmE (mnmE) CSB-YP461517EYZ
CSB-EP461517EYZ
CSB-BP461517EYZ
CSB-MP461517EYZ
CSB-EP461517EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問(wèn)題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>